Sponsored By:

7 Biotechnology Stocks to Sell Now

DSCO, ACHN, GHDX, ACOR, AMRN, EXEL, TSRX slump in weekly rankings

   

This week, the overall grades of seven Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Discovery Laboratories (NASDAQ:DSCO) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, DSCO also gets F’s. For a full analysis of DSCO stock, visit Portfolio Grader.

Achillion (NASDAQ:ACHN) is having a tough week. The company’s rating falls from C to a D. Achillion focuses on the discovery, development and commercialization of innovative treatments for infectious diseases. The stock also rates an F in Equity. The stock price has fallen 9.2% over the past month, worse than the 0.8% decrease the Nasdaq has seen over the same period of time. As of Feb. 27, 2013, 16.2% of outstanding Achillion shares were held short. For more information, get Portfolio Grader’s complete analysis of ACHN stock.

The rating of Genomic Health (NASDAQ:GHDX) declines this week from C to a D. Genomic Health is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The stock also gets an F in Earnings Revisions. The stock currently has a trailing PE Ratio of 112.90. For a full analysis of GHDX stock, visit Portfolio Grader.

Acorda Therapeutics (NASDAQ:ACOR) gets weaker ratings this week as last week’s C drops to a D. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The stock gets F’s in Earnings Revisions and Sales Growth. To get an in-depth look at ACOR, get Portfolio Grader’s complete analysis of ACOR stock.

Amarin’s (NASDAQ:AMRN) rating weakens this week, dropping to a D versus last week’s C. Amarin focuses on developing the treatment for cardiovascular disease in the field of lipid science. The stock gets F’s in Earnings Growth, Earnings Revisions, Equity, and Cash Flow. As of Feb. 27, 2013, 16% of outstanding Amarin shares were held short. For more information, get Portfolio Grader’s complete analysis of AMRN stock.

Exelixis’ (NASDAQ:EXEL) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Exelixisis a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The stock receives F’s in Earnings Growth, Earnings Momentum, and Equity. Margin Growth and Sales Growth also get F’s. Share prices fell 6.5% over the past month. As of Feb. 27, 2013, 20.3% of outstanding Exelixis shares were held short. To get an in-depth look at EXEL, get Portfolio Grader’s complete analysis of EXEL stock.

Trius Therapeutics (NASDAQ:TSRX) experiences a ratings drop this week, going from last week’s C to a D. Trius Therapeutics is a biopharmaceutical company. The stock gets F’s in Earnings Growth, Earnings Momentum, and Equity. Cash Flow and Sales Growth also get F’s. For more information, get Portfolio Grader’s complete analysis of TSRX stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, http://investorplace.com/2013/02/7-biotechnology-stocks-to-sell-now-dsco-achn-ghdx/.

©2014 InvestorPlace Media, LLC

Comments are currently unavailable. Please check back soon.